Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833.
AZD9833 is a best in class profile, next generation oral selective estrogen receptor degrader (SERD) with an established pharmacokinetic profile in the clinic – specifically, AZD9833 is a full antagonist and complete degrader of estrogen receptor in all preclinical cell line models tested.